

2. (Amended) [Peptide] The anti-HIV peptide according to claim 1, [according to which] wherein the antigen [of the envelope] is [represented by] the envelope protein gp160.

3. (Amended) [Peptide] The anti-HIV peptide according to claim 1 [or 2], [characterized in that this] wherein the peptide [may comprise the sequences 1 to 11] is selected from the group consisting of:

SEQ. ID. NO.: 1	Phe Asn Leu Thr His Phe Leu _L
SEQ. ID. NO.: 2	Glu Gly Trp His Ala His Thr _L
SEQ. ID. NO.: 3	Lys Leu Asn Trp Met Phe Thr _L
SEQ. ID. NO.: 4	Ser Thr Asn Trp Met Phe Thr _L
SEQ. ID. NO.: 5	Ala Met Pro Leu Pro Tyr Thr Phe _L
SEQ. ID. NO.: 6	Asp Ser His Thr Pro Gln Arg _L
SEQ. ID. NO.: 7	Val Ser Phe Thr Pro Ser Phe
SEQ. ID. NO.: 8	His Ala Ala Leu Ser Met Asn Thr His Ala Leu Met _L
SEQ. ID. NO.: 9	Ala Trp His Glu Ser Arg Ala _L
SEQ. ID. NO.: 10	Phe Lys Thr Ala Tyr Pro Thr _L <u>and</u>
SEQ. ID. NO.: 11	Ser His Ala Leu Pro Leu Thr Trp Ser Thr Ala Ala _L

4. (Amended) [Peptide] A peptide comprising [the linkage of] at least two anti-HIV peptides according to [one of claims 1 to] claim 3.

5. (Amended) [Peptide] The peptide according to claim 4, [comprising the duplication of identical] wherein the anti-HIV peptides are identical.

6. (Amended) [Peptide] The peptide according to claim 5, [in which the coupling of] wherein the two anti-HIV peptides [occurs] are linked by means of a ["spacer"] spacer arm consisting of the amino acid sequence Gly Pro Gly.

7. (Amended) [Conjugate] A conjugate comprising at least one peptide according to [one of claims 1 to 6.] claim 3 bound to a carrier molecule [in order to induce or enhance the immunogenicity of said peptides], wherein the immunogenicity of the peptide is induced or enhanced.

8. (Amended) [Conjugate] The conjugate according to claim 7, [according to which] wherein the carrier molecule comprises at least one helper T epitope of the HIV virus.

9. (Amended) [Conjugate] The conjugate according to claim 8, [whose] wherein the carrier molecule comprises [the] HIV p24E [and] or T1 epitopes [of the HIV virus].

10. (Amended) [Conjugate] The conjugate according to claim 9, comprising a first peptide [resulting from the duplication of] selected from the sequences NO: 1, NO: 3 [or] and NO: 4 [according to claim 6] linked to an identical second peptide by a Gly Pro Gly spacer to form a linked peptide, said linked peptide being bound on the N-terminal side by a spacer to the p24E epitope and the C-terminal side by a spacer to the T1 epitope [by means of two "spacer" arms].

11. (Amended) [Conjugate] The conjugate according to claim 10, [characterized in that] wherein the [2 spacer arms] spacers bound to the p24E and T1 epitopes are identical and consist of the linkage Gly Pro Gly and [in that it] the linked peptide comprises any one of [the sequences] SEQ. ID. NOs.: 12 to 14;

SEQ. ID. NO.: 12 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg
 Phe Tyr Lys Gly Pro Gly Lys Leu Asn Trp Met Phe
 Thr Gly Pro Gly Lys Leu Asn Trp Met Phe Thr Gly
 Pro Gly Lys Gln Ile Ile Asn Met Trp Gln Glu Val
 Glu Lys Ala Met Tyr Ala

SEQ. ID. NO.: 13 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg
Phe Tyr Lys Gly Pro Gly Ser Thr Asn Trp Met Phe
Thr Gly Pro Gly Ser Thr Asn Trp Met Phe Thr Gly
Pro Gly Lys Gln Ile Ile Asn Met Trp Gln Glu Val
Glu Lys Ala Met Tyr Ala

SEQ. ID. NO.: 14 Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Tyr Lys Gly Pro
Gly Phe Asn Leu Thr His Phe Leu Gly Pro Gly Phe Asn Leu Thr His Phe
Leu Gly Pro Gly Lys Gln Ile Ile Asn Met Trp Gln Glu Val Glu Lys Ala
Met Tyr Ala

12. (Amended) [Recombinant] A recombinant vector comprising a functional expression cassette [allowing the expression of] comprising a polynucleotide encoding a peptide according to one of claims [1 to 11] 3, 4, 8, and 11.

13. (Amended) [Recombinant] The recombinant vector according to claim 12, [characterized in that it] wherein the vector is an adenovirus, a poxvirus, a baculovirus, a bacteriophage or a plasmid.

14. (Amended) [Therapeutic] A therapeutic or prophylactic composition for HIV infection[, in particular intended for vaccine use, whose] wherein the active ingredient comprises a peptide according to one of claims [1 to 11] 3, 4, 8, and 11 and/or a recombinant vector encoding said peptide [according to either of claims 12 and 13].

15. (Amended) [Composition] The composition according to claim 14, [whose] wherein the active ingredient is [in the form of a formulation] combined with a compatible adjuvant for administration of an effective dose by the mucosal or parenteral route.